900 mg daily of gabapentin was effective for hot flashes in women with breast cancer

March 2006
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p41
Academic Journal
This article presents a study which states that 900 mg daily of gabapentin was effective for hot flashes in women with breast cancer. In the study, 420 women 18 years of age with breast cancer who were having an average 2 hot flashes daily. 71% of women were taking tamoxifen. Women receiving chemotherapy or taking venlafaxine, clonidine, or anticonvulsants were not eligible, but use of other antidepressants was allowed. Exclusion criteria included pregnancy; breastfeeding; use of steroidal contraception; and recent history of cardiovascular, cerebrovascular, hepatic, or renal problems.


Related Articles

  • Letrozole. Keating, Gillian M. // Drugs;2009, Vol. 69 Issue 12, p1681 

    Letrozole (Femara®) is a third-generation, nonsteroidal aromatase inhibitor. Adjuvant therapy with letrozole is more effective than tamoxifen in postmenopausal women with hormone-responsive early breast cancer, and extended adjuvant therapy with letrozole after the completion of adjuvant...

  • Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? M. M. Regan; O. Pagani; B. Walley; R. Torrisi; E. A. Perez; P. Francis; G. F. Fleming; K. N. Price; B. Thürlimann; R. Maibach; M. Castiglione-Gertsch; A. S. Coates; A. Goldhirsch; R. D. Gelber; for the SOFT/TEXT/PERCHE Steering Committee and the International Breast Cancer Study Group // Annals of Oncology;Jul2008, Vol. 19 Issue 7, p1231 

    Background: The role of chemotherapy in addition to combined endocrine therapy for premenopausal women with endocrine-responsive early breast cancer remains an open question, yet trials designed to answer it have repeatedly failed to adequately accrue. The International Breast Cancer Study Group...

  • Adjuvant Endocrine Therapy for Breast Cancer: Don't Ditch the Switch! Puhalla, Shannon; Jankowitz, Rachel C.; Davidson, Nancy E. // JNCI: Journal of the National Cancer Institute;Sep2011, Vol. 103 Issue 17, p1280 

    The authors comment on two studies on breast cancer, one suggesting the positive benefits of switching tamoxifen and aromatase inhibitors (AI) and another on the adjuvant trials of AI versus tamoxifen in postmenopausal women. According to the authors, the findings of both studies are far from...

  • Antidepressants may 'depress' effects of tamoxifen in breast cancer.  // Reactions Weekly;6/6/2009, Issue 1255, p1 

    The article deals with a study presented at the Annual Meeting of the American Society of Clinical Oncology which examined the concomitant use of tamoxifen and certain antidepressants in women with breast cancer. 90% was the average compliance with tamoxifen therapy throughout the study period....

  • Treatment of oestrogen deficiency in women with previous breast cancer. Marsden, Jo // Journal of the British Menopause Society;2000 Supplement, Vol. 6, p18 

    The article discusses the management of estrogen deficiency in women with previous breast cancer. The widespread use of tamoxifen, chemotherapy and gonadotropin-releasing hormone agonists suppress the effects of endogenous estrogens and may induce a premature menopause. Low-dose progestogens and...

  • Breast cancer radiotherapy and cardiac risk: The 15-year paradox! Munshi, Anusheel // Journal of Cancer Research & Therapeutics;Oct-Dec2007, Vol. 3 Issue 4, p190 

    The article provides information related to breast cancer. Breast cancer is the leading cause of death in women in the world. Management of breast cancer requires a multimodality approach and an integration of the services of surgery, radiotherapy, and chemotherapy. According to the latest Early...

  • Undertreatment of elderly women with breast cancer.  // PharmacoEconomics & Outcomes News;11/18/2006, Issue 516, p7 

    The article highlights the findings of a U.S.-based study which stated that older women with early-stage breast cancer are undertreated. The data used by the researchers in the study is presented. The researchers found that increasing age was associated with lower receipt of standard primary...

  • The TP53 gene polymorphisms and survival of sporadic breast cancer patients. Bišof, V.; Salihović, M.; Narančić, N.; Škarić-Jurić, T.; Jakić-Razumović, J.; Janićijević, B.; Rudan, P. // Medical Oncology;Jun2012, Vol. 29 Issue 2, p472 

    The TP53 gene polymorphisms, Arg72Pro and PIN3 (+16 bp), can have prognostic and predictive value in different cancers including breast cancer. The aim of the present study is to investigate a potential association between different genotypes of these polymorphisms and clinicopathological...

  • Successful pregnancy after breast cancer therapy: dream or reality? Kontzoglou, Konstantinos; Stamatakos, Michael; Tsaknaki, Sofia; Goga, Helen; Kostakis, Alkiviades; Safioleas, Michael // International Seminars in Surgical Oncology;2009, Vol. 6, p1 

    Background: Nowadays, more breast cancer patients want to have children after the diagnosis of cancer. The purpose of this study is to review the possibility and risks of giving birth among women with breast cancer previously treated by chemotherapy. Case presentation: Two young women aged 28...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics